BTIG Research Raises Liquidia (NASDAQ:LQDA) Price Target to $111.00

Key Points

• BTIG Research raised Liquidia’s price target to $111 from $109 and maintained a “buy” rating, implying approximately 40% upside from the reported $79.07 share price. Analysts collectively rate the stock “Moderate Buy,” with an average target of $90.
• Liquidia reported strong growth, including $171.7 million in quarterly revenue, up more than 1,800% year over year, although earnings per share of $0.74 slightly missed consensus estimates.
• The stock fell 10.2% during Wednesday’s trading, while recent insider selling—including a director’s $8.95 million sale—may add pressure despite increased institutional ownership and a reaffirmed long-term revenue goal exceeding $1 billion in 2027.

Liquidia (NASDAQ:LQDA - Get Free Report) had its target price hoisted by research analysts at BTIG Research from $109.00 to $111.00 in a report released on Wednesday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. BTIG Research's price objective points to a potential upside of 40.38% from the company's current price.

LQDA has been the subject of a number of other research reports. Oppenheimer set a $75.00 price target on Liquidia in a report on Friday, June 5th. Zacks Research raised Liquidia from a "hold" rating to a "strong-buy" rating in a report on Tuesday, May 5th. Raymond James Financial reissued a "strong-buy" rating and issued a $68.00 price objective on shares of Liquidia in a research report on Thursday, June 4th. Lifesci Capital restated a "market perform" rating and set a $90.00 price objective on shares of Liquidia in a research report on Wednesday. Finally, Bank of America restated a "neutral" rating and issued a $79.00 price target (up from $64.00) on shares of Liquidia in a research note on Monday, June 29th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Liquidia has an average rating of "Moderate Buy" and an average target price of $90.00.

Liquidia Stock Down 10.2%

Shares of NASDAQ:LQDA traded down $8.98 during trading on Wednesday, hitting $79.07. 3,040,638 shares of the company were exchanged, compared to its average volume of 1,774,534. Liquidia has a fifty-two week low of $21.15 and a fifty-two week high of $93.61. The stock has a market cap of $7.03 billion, a price-to-earnings ratio of 564.83 and a beta of 0.58. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18. The firm has a fifty day moving average price of $77.76 and a two-hundred day moving average price of $54.51.

Liquidia (NASDAQ:LQDA - Get Free Report) last released its earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.02). The firm had revenue of $171.68 million during the quarter, compared to the consensus estimate of $168.48 million. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. Liquidia's quarterly revenue was up 1842.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.49) earnings per share. As a group, research analysts anticipate that Liquidia will post 3.02 earnings per share for the current fiscal year.

Insider Transactions at Liquidia

In other news, Director Stephen M. Bloch sold 100,000 shares of Liquidia stock in a transaction on Thursday, July 23rd. The stock was sold at an average price of $89.48, for a total value of $8,948,000.00. Following the transaction, the director owned 501,477 shares in the company, valued at approximately $44,872,161.96. This trade represents a 16.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Dana Boyle sold 1,600 shares of the firm's stock in a transaction dated Monday, July 27th. The shares were sold at an average price of $87.53, for a total value of $140,048.00. Following the completion of the sale, the chief accounting officer directly owned 167,919 shares in the company, valued at $14,697,950.07. This trade represents a 0.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 1,781,861 shares of company stock worth $124,407,112. 25.60% of the stock is owned by insiders.

Institutional Trading of Liquidia

A number of hedge funds have recently made changes to their positions in LQDA. GSA Capital Partners LLP lifted its holdings in Liquidia by 63.6% during the 4th quarter. GSA Capital Partners LLP now owns 63,176 shares of the company's stock worth $2,179,000 after buying an additional 24,555 shares during the period. The Manufacturers Life Insurance Company boosted its stake in shares of Liquidia by 63.3% in the 1st quarter. The Manufacturers Life Insurance Company now owns 58,265 shares of the company's stock valued at $2,199,000 after purchasing an additional 22,592 shares during the last quarter. State of New Jersey Common Pension Fund D bought a new position in Liquidia during the fourth quarter worth $709,000. WCG Wealth Advisors LLC boosted its position in Liquidia by 98.2% during the fourth quarter. WCG Wealth Advisors LLC now owns 54,411 shares of the company's stock valued at $1,877,000 after acquiring an additional 26,957 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Liquidia by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 4,013,888 shares of the company's stock worth $138,439,000 after acquiring an additional 52,671 shares in the last quarter. 64.54% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: YUTREPIA sales accelerated. Net product sales reached approximately $170.4 million in the second quarter, up 31% from the first quarter. Liquidia reported roughly 5,900 unique prescriptions and more than 5,000 patients treated since the product launched in June 2025. Liquidia Corporation Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Profitability and cash generation improved. Liquidia posted $171.7 million in revenue, $74.7 million in net income and $96.3 million in adjusted EBITDA, marking its fourth consecutive quarter of increasing profitability. Cash and equivalents rose to approximately $284.2 million from $190.7 million at the end of 2025. Liquidia Q2 Net Income Reaches $74.7 Million As YUTREPIA Sales Rise
• Positive Sentiment: Management maintained its long-term growth outlook. Liquidia reaffirmed its target of more than $1 billion in net revenue in 2027 and is advancing 10 clinical studies involving YUTREPIA and the L606 inhaled treprostinil program.
• Neutral Sentiment: Institutional interest remains mixed but generally supportive. Recent filings showed major investors including BlackRock and State Street adding shares, although some funds reduced their positions.
• Negative Sentiment: Adjusted expectations contributed to the selloff. Diluted EPS of $0.74 was slightly below the approximately $0.76 analyst consensus cited by several reports, despite revenue exceeding expectations. Another estimate source placed consensus at $0.70, highlighting differences among analyst forecasts. Liquidia shares fall after second-quarter earnings miss despite revenue growth
• Negative Sentiment: Spending is increasing. Research and development expenses rose to $17.2 million from $6.0 million a year earlier as Liquidia funds the Phase 3 L606 program. The company’s elevated valuation also leaves less room for disappointing results.
• Negative Sentiment: Insider selling is a potential overhang. Reported insider activity over the past six months consisted overwhelmingly of sales, including transactions by senior executives, with only one reported purchase.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company's lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source